Microbial Matters, a podcast introducing latest microbiome research. I’m Jerry Zhang, a chemical biologist working on human microbiome. In this Podcast, I’m going to share with you newest advances in microbiome research, especially those related to human health.

What is the link between gut microbiota and metabolic diseases in humans? Which study found the link between obesity and gut microbiota? How does gut microbiota affect Type 2 diabetes? What is the effect of the common antidiabetic drug metformin on intestinal flora? Why are some diabetes patients resistant to acarbose? What is the role of dipeptidyl peptidase 4 (DPP4) in blood sugar regulation? What is the effect of DPP-4 inhibitors on Bacteroides thetaiotaomicron? What are “microbial-host isozymes”? What impact does bacterial DPP4 have on host glucose tolerance? Why doesn't sitagliptin work for some people with diabetes? How does Bacteroides thetaiotaomicron cause trouble? Which active ingredient in traditional Chinese medicine may be a new type of antidiabetic drug?

1.Tian, J. et al. Inactivation of the antidiabetic drug acarbose by human intestinal microbial-mediated degradation. Nat Metabolism 1–14 (2023) doi:10.1038/s42255-023-00796-w.

2.Keller, L. J. et al. Chemoproteomic identification of a DPP4 homolog in Bacteroides thetaiotaomicron. Nat. Chem. Biol. 1–11 (2023) doi:10.1038/s41589-023-01357-8.

3.Wang, K., Zhang, Z., Hang, J., Liu, J., Guo, F., Ding, Y., Li, M., Nie, Q., Lin, J., Zhuo, Y., et al. (2023). Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science 381. 10.1126/science.add5787.

Links to original articles：www.nature.com； www.nature.com； www.science.org

Support this podcast: anchor.fm